Maze Therapeutics Reports No License Revenue and $30.1 Million Net Loss for Q3 2025

Maze Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded no license revenue during the quarter, a stark contrast to the $2.5 million generated in the same period last year. For the nine months ending September 30, 2025, Maze also reported no license revenue, down from $167.5 million in the previous year, primarily due to the absence of new licensing agreements following substantial upfront payments received in 2024. The company incurred a net loss of $30.1 million for the quarter and $96.6 million for the nine months, compared to a net loss of $24.8 million and a net income of $81.8 million, respectively, in the prior year.

Operating expenses increased significantly, with total expenses for the third quarter reaching $33.0 million, up from $26.7 million in the same quarter of 2024. Research and development costs rose to $25.2 million from $19.9 million, driven by higher personnel-related costs and clinical trial expenses associated with ongoing studies for its lead programs, MZE829 and MZE782. General and administrative expenses also increased to $7.8 million from $6.9 million, reflecting higher personnel costs and facility expenses.

Maze Therapeutics has made strategic moves to bolster its financial position, including a successful initial public offering (IPO) in February 2025, which raised approximately $127.8 million, and a private placement in September 2025 that generated about $141.3 million. As of September 30, 2025, the company reported cash, cash equivalents, and marketable securities totaling $383.9 million, providing a solid liquidity position to support ongoing research and development activities.

The company has also made progress in its clinical trials, announcing positive results from a Phase 1 study of MZE782, which demonstrated safety and tolerability in healthy volunteers. This trial's success positions Maze to initiate two Phase 2 proof-of-concept trials in 2026, targeting phenylketonuria and chronic kidney disease. However, the company continues to face challenges, including the need for substantial additional capital to fund its operations and the uncertainty surrounding the commercialization of its therapeutic candidates.

Looking ahead, Maze Therapeutics anticipates continued operating losses as it invests heavily in research and development. The company plans to finance its operations through a combination of equity offerings, collaborations, and licensing arrangements. Despite its current cash reserves, Maze acknowledges the potential need for further capital to sustain its growth and development efforts in the competitive biopharmaceutical landscape.